Abbott Wins FDA Nod for World's First Dual Glucose-Ketone Sensor

Abbott received FDA authorization for the world's first dual glucose-ketone sensor, the Libre Duo 10 Day System, which provides real-time glucose monitoring and continuous ketone tracking to alert diabetic patients of diabetic ketoacidosis risk. The device aims to launch in the US later in 2026 and meets FDA's integrated continuous monitoring standards.

This Wire brief sits within Fusion42's coverage of Medtech.